Quebec’s stem cell donor registry swelled in 2014, but Marc-André Skelling … – Montreal Gazette
Montreal Gazette |
Quebec’s stem cell donor registry swelled in 2014, but Marc-André Skelling …
Montreal Gazette Skelling’s cancer returned last March after being in remission twice. He underwent chemotherapy, radiotherapy and a failed autograft. His last hope is a stem cell transplant from either a compatible donor’s bone marrow or umbilical cord blood, although … |
|
The Biological Clock Regulating Skin Stem Cell Metabolism
Science 2.0 A study of circadian rhythms in skin stem cells finds that this biological clock plays a key role in coordinating daily metabolic cycles and cell division. The paper shows how the body’s intrinsic day-night cycles protect and nurture stem cell … Circadian Rhythms Regulate Skin Stem Cell Metabolism, ExpansionSleep Review |
|
The Biological Clock Regulating Skin Stem Cell Metabolism
Science 2.0 A study of circadian rhythms in skin stem cells finds that this biological clock plays a key role in coordinating daily metabolic cycles and cell division. The paper shows how the body’s intrinsic day-night cycles protect and nurture stem cell … Circadian Rhythms Regulate Skin Stem Cell Metabolism, ExpansionSleep Review |
Healthline |
Most MS Patients Who Received Stem Cell Transplants Still in Remission 3 …
Healthline Three years after the stem cell study HALT-MS began, many of the multiple sclerosis (MS) patients who took part are still in remission. The phase 2 study has demonstrated impressive results by rebuilding the immune system using a patient’s own stem cells. |
Healthline |
Most MS Patients Who Received Stem Cell Transplants Still in Remission 3 …
Healthline Most of the multiple sclerosis (MS) patients who took part in the cutting-edge stem cell study HALT-MS are still in remission years later. The phase 2 study has demonstrated impressive results by rebuilding the immune system using a patient’s own stem … |
Regulatory Focus |
EU’s First Stem Cell Treatment Recommended by EMA
Regulatory Focus A major milestone in stem cell therapy was reached in December 2014 when a European Medicines Agency (EMA) committee recommended the conditional approval of Holoclar, the first stem–cell product to be recommended for approval in the EU. |
Regulatory Focus |
EU’s First Stem Cell Treatment Recommended by EMA
Regulatory Focus A major milestone in stem cell therapy was reached in December 2014 when a European Medicines Agency (EMA) committee recommended the conditional approval of Holoclar, the first stem–cell product to be recommended for approval in the EU. |